Goldenwell Biotech, Inc. (GWLL)
Goldenwell Biotech, Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Solon, OH, US. The stock last traded at $0.69, up 0.00% on the session, giving a market capitalisation of $68.3M. On trailing twelve-month figures it carries a trailing P/E of -255.44, a net margin of -1130.4%. Its beta of 4.60 implies it has historically moved more than the broad market.
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
Goldenwell Biotech, Inc. is most often compared with the following Healthcare names: